• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.

作者信息

Allmeroth Kira, Horn Moritz, Kroef Virginia, Miethe Stephan, Müller Roman-Ulrich, Denzel Martin S

机构信息

Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Str. 9b, D-50931, Cologne, Germany.

Acus Laboratories GmbH c/o Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Str. 9b, D-50931, Cologne, Germany.

出版信息

Leukemia. 2021 Mar;35(3):887-892. doi: 10.1038/s41375-020-0989-4. Epub 2020 Jul 20.

DOI:10.1038/s41375-020-0989-4
PMID:32690882
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7932915/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e422/7932915/1e1bccb2ee4d/41375_2020_989_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e422/7932915/1cfb4140a121/41375_2020_989_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e422/7932915/1e1bccb2ee4d/41375_2020_989_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e422/7932915/1cfb4140a121/41375_2020_989_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e422/7932915/1e1bccb2ee4d/41375_2020_989_Fig2_HTML.jpg

相似文献

1
Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.蛋白酶体β5亚基（PSMB5）中的硼替佐米耐药突变决定了多发性骨髓瘤对第二代蛋白酶体抑制剂的反应。
Leukemia. 2021 Mar;35(3):887-892. doi: 10.1038/s41375-020-0989-4. Epub 2020 Jul 20.
2
Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.用于研究多发性骨髓瘤中蛋白酶体抑制剂耐药机制和克服策略的新型细胞系模型。
Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1666-1676. doi: 10.1016/j.bbadis.2019.04.003. Epub 2019 Apr 4.
3
A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.一种临床相关的脉冲处理生成了一种硼替佐米耐药的骨髓瘤细胞系，该细胞系缺乏蛋白酶体突变，并且对 Bcl-2 抑制剂 venetoclax 敏感。
Sci Rep. 2022 Jul 27;12(1):12788. doi: 10.1038/s41598-022-17239-3.
4
Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response.通过评估未折叠蛋白反应预测多发性骨髓瘤对蛋白酶体抑制剂硼替佐米的反应。
Blood Cancer J. 2016 Jun 10;6(6):e432. doi: 10.1038/bcj.2016.40.
5
RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.药物基因组学 RNAi 筛选鉴定多发性骨髓瘤蛋白酶体抑制剂敏感性的调节剂，包括 CDK5。
Blood. 2011 Apr 7;117(14):3847-57. doi: 10.1182/blood-2010-08-304022. Epub 2011 Feb 2.
6
Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.多发性骨髓瘤中蛋白酶体抑制剂耐药机制的更新。
Asia Pac J Clin Oncol. 2021 Feb;17(1):29-35. doi: 10.1111/ajco.13459. Epub 2020 Sep 13.
7
[Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].[蛋白酶体抑制剂硼替佐米在多发性骨髓瘤治疗中的作用机制及敏感性决定因素]
Rinsho Ketsueki. 2016 May;57(5):537-45. doi: 10.11406/rinketsu.57.537.
8
Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma.通过模拟治疗学习构建的基因网络可以预测多发性骨髓瘤中蛋白酶体抑制剂的获益。
Clin Cancer Res. 2020 Nov 15;26(22):5952-5961. doi: 10.1158/1078-0432.CCR-20-0742. Epub 2020 Sep 10.
9
Spectrum and functional validation of PSMB5 mutations in multiple myeloma.多种骨髓瘤中 PSMB5 突变的频谱和功能验证。
Leukemia. 2019 Feb;33(2):447-456. doi: 10.1038/s41375-018-0216-8. Epub 2018 Jul 19.
10
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.硼替佐米或地塞米松治疗复发性多发性骨髓瘤患者 20S 蛋白酶体β亚基基因的序列分析。
Blood. 2012 Nov 29;120(23):4513-6. doi: 10.1182/blood-2012-05-426924. Epub 2012 Sep 27.

引用本文的文献

1
The Transcription Axes ERK-Elk1, JNK-cJun, and JAK-STAT Promote Autophagy Activation and Proteasome Inhibitor Resistance in Prostate Cancer Cells.转录轴ERK-Elk1、JNK-cJun和JAK-STAT促进前列腺癌细胞中的自噬激活和蛋白酶体抑制剂抗性。
Curr Issues Mol Biol. 2025 May 12;47(5):352. doi: 10.3390/cimb47050352.
2
A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma.硼替佐米耐药多发性骨髓瘤中循环miRNA生物标志物的预后、诊断和治疗的主题分析
SAGE Open Med. 2025 Apr 26;13:20503121251328486. doi: 10.1177/20503121251328486. eCollection 2025.
3
Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical Implications.
单细胞分析对多发性骨髓瘤的见解：克隆进化、微环境、治疗逃逸及临床意义
Cancers (Basel). 2025 Feb 14;17(4):653. doi: 10.3390/cancers17040653.
4
Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients.蛋白酶体β5亚基（PSMB5）在硼替佐米耐药的多发性骨髓瘤患者骨髓单个核细胞中的预后价值及其与微管相关蛋白1轻链3Ⅱ型（LC3Ⅱ）和活性氧水平的相关性
Curr Issues Mol Biol. 2025 Jan 6;47(1):32. doi: 10.3390/cimb47010032.
5
MiR-34c-5p Inhibition Affects Bax/Bcl2 Expression and Reverses Bortezomib Resistance in Multiple Myeloma Cells.微小RNA-34c-5p抑制影响多发性骨髓瘤细胞中Bax/Bcl2表达并逆转硼替佐米耐药性
Indian J Hematol Blood Transfus. 2024 Oct;40(4):596-603. doi: 10.1007/s12288-024-01742-w. Epub 2024 Apr 11.
6
Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.多发性骨髓瘤获得硼替佐米耐药：从机制到策略。
Curr Treat Options Oncol. 2024 Nov;25(11):1354-1365. doi: 10.1007/s11864-024-01273-6. Epub 2024 Oct 21.
7
AP-1 inhibitor induces ferroptosis via the PI3K/AKT pathway in multiple myeloma cells.AP-1抑制剂通过PI3K/AKT途径诱导多发性骨髓瘤细胞发生铁死亡。
Heliyon. 2024 Jul 10;10(14):e34397. doi: 10.1016/j.heliyon.2024.e34397. eCollection 2024 Jul 30.
8
In vitro evolution and whole genome analysis to study chemotherapy drug resistance in haploid human cells.体外进化和全基因组分析研究人类单倍体细胞中的化疗药物耐药性。
Sci Rep. 2024 Jun 18;14(1):13989. doi: 10.1038/s41598-024-63943-7.
9
The Efficacy of Carfilzomib Treatment in Bortezomib-Refractory Patients-Real Life Experience in a Tertiary Romanian Hospital.卡非佐米治疗硼替佐米难治性患者的疗效——罗马尼亚一家三级医院的真实病例经验
J Clin Med. 2024 Apr 9;13(8):2171. doi: 10.3390/jcm13082171.
10
MiR-383 sensitizes osteosarcoma cells to bortezomib treatment via down-regulating PSMB5.miR-383 通过下调 PSMB5 使骨肉瘤细胞对硼替佐米治疗敏感。
Mol Biol Rep. 2024 Jan 22;51(1):170. doi: 10.1007/s11033-023-08964-7.